BRITISH COLUMBIA, Canada, March 6 /PRNewswire/ --
- Company Receives Allowance of Patent Claims in the U.S. and in India -
- InNexus Biotechnology CEO Highlighted in Nature Biotechnology -
InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that it has received a notice of allowance on patent claims in the United States (Serial No. 11/119,404) and a patent grant in India (National Phase Application No. 2424/CHENP/2005) further expanding its protection of InNexus' DXL(TM) technology.
Speaking on today's announcement, InNexus Chairman and CEO, Jeff Morhet said, DXL(TM) antibodies that penetrate directly into cells, is an exciting achievement for InNexus and our industry. As we've continued to expand our patent portfolio and discover new technologies to develop products, the team has aggressively pursued patent protection for our novel inventions. Patents are the currency of our industry and a driver for enhanced value for our shareholders and potential use of these cell penetrating DXL(TM) antibodies represents another frontier for the use of antibodies for therapeutic and diagnostic applications.
Dr. Thomas Kindt, Chief Scientific Officer of InNexus said, The claims in these patents are directed toward the addition of membrane transport sequences to DXL antibodies, which facilitate penetration of DXL(TM) antibodies into cancer cells. The ability to direct our DXL(TM) antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and applications also include coverage for new molecules and products of InNexus. We like to say We Build Better Antibodies and today, we demonstrated that once again.
InNexus also announced that Jeff Morhet, Chairman and CEO, was recently highlighted and quoted in an article titled JAMA study casts cloud over biologic safety in the January 2009 issue of Nature Biotechnology. A copy of the article can be downloaded at: http://www.nature.com/nbt/journal/v27/n1/pdf/nbt0109-11.pdf. Nature Biotechnology is a widely read academic journal published by Nature Publishing Group, a division of Macmillan Publishers Ltd., covering the science and business of biotechnology.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Jeff Morhet, Chairman Chief Executive Officer of InNexus Biotechnology Inc., +1-480-862-7500